Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $8.3 million.

  • Maxcyte's Accumulated Expenses rose 134.21% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 134.21%. This contributed to the annual value of $8.3 million for FY2024, which is 2632.89% down from last year.
  • As of Q3 2025, Maxcyte's Accumulated Expenses stood at $8.3 million, which was up 134.21% from $6.4 million recorded in Q2 2025.
  • Maxcyte's 5-year Accumulated Expenses high stood at $11.3 million for Q4 2023, and its period low was $3.9 million during Q1 2022.
  • Moreover, its 5-year median value for Accumulated Expenses was $7.0 million (2023), whereas its average is $7.1 million.
  • In the last 5 years, Maxcyte's Accumulated Expenses surged by 7859.1% in 2023 and then crashed by 2632.89% in 2024.
  • Maxcyte's Accumulated Expenses (Quarter) stood at $6.5 million in 2021, then grew by 26.7% to $8.3 million in 2022, then soared by 36.35% to $11.3 million in 2023, then fell by 26.33% to $8.3 million in 2024, then increased by 0.05% to $8.3 million in 2025.
  • Its Accumulated Expenses was $8.3 million in Q3 2025, compared to $6.4 million in Q2 2025 and $5.0 million in Q1 2025.